HAVCR2 and leukemia: In patients with B-ALL, Finney et al. observed that engrafted anti-CD19 CAR-T cells from minimal residual disease (MRD)-negative and durable leukemia-free patients expressed lower levels of LAG3 and TIM3 compared with those from MRD-positive or non-durable leukemia-free patients [26].